Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus

Brain Research

Volumn 1309, Issue , 2010, Pages 110-115

  Hamaue, Naoya ^a   Ogata, Akihiko ^b   Terado, Mutsuko ^a   Tsuchida, Shirou ^a   Yabe, Ichiro ^b   Sasaki, Hidenao ^b   Hirafuji, Masahiko ^a   Togashi, Hiroko ^a   Aoki, Takashi ^a  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

COMT; DA; Motor activity; Parkinson's disease; Striatum; Treatment

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; ENTACAPONE; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; JAPANESE ENCEPHALITIS VIRUS; MONOTHERAPY; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CORPUS STRIATUM; DOPA DECARBOXYLASE; DOPAMINE; DRUG COMBINATIONS; DRUG SYNERGISM; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; ENZYME INHIBITORS; LEVODOPA; NITRILES; PARKINSONIAN DISORDERS; RATS; RATS, INBRED F344; TREATMENT OUTCOME;

JAPANESE ENCEPHALITIS VIRUS; RATTUS;

EID: 72049087190     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.10.055     Document Type: Article

References (27)

1. Chong D.J., Suchowersky O., Szumlanski C., Weinshilboum R.M., Brant R., and Campbell R.C. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin. Neuropharmacol. 23 (2000) 143-148
2. Contin M., Martinelli P., Mochi M., Riva R., Albani F., and Baruzzi A. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease. Mov. Disord. 20 (2005) 734-739
3. Fung V.S., Herawati L., and Wan Y. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Mov. Disord. 24 (2009) 25-31
4. 3H]dopa in various regions of the brain. J. Neurochem. 13 (1966) 655-669
5. Hamaue N., Minami M., Terado M., Hirafuji M., Endo T., Machida M., Hiroshige T., Ogata A., Tashiro K., Saito H., and Parvez S.H. Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus. Neurotoxicology 25 (2004) 205-213
6. Hamaue N., Ogata A., Terado M., Endo T., Makiura T., Hirafuji M., Yasui K., Nagashima K., Tashiro K., Minami M., and Parvez S.H. Selegiline effects on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus. Biog. Amines 16 (2001) 523-530
7. Hamaue N., Ogata A., Terado M., Ohno K., Kikuchi S., Sasaki H., Tashiro K., Hirafuji M., and Minami M. Brain catecholamine alteration and pathological features with aging in Parkinson's disease model rat induced by the Japanese encephalitis virus. Neurochem. Res. 31 (2006) 1451-1455
8. Heikkinen H., Varhe A., Laine T., Puttonen J., Kela M., Kaakkola S., and Reinikainen K. Entacapone improve the availability of l-dopa in plasma by decreasing its peripheral metabolism of l-dopa/carbidopa dose. Br. J. Clin. Pharmacol. 54 (2002) 363-371
9. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59 (2000) 1233-1250
10. Kaakkola S., Gordin A., Larvinen M., Wikberg T., Schultz E., Nissinen E., Pentikainen P.J., and Tata H. Effect of a novel catecholamine-O-methyltransferase inhibitor, entacapone on the metabolism of L-dopa in healthy volunteers. Clin. Neurophrmacol. 13 (1990) 436-447
11. Kaakkola S., and Wurtman R.J. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res. 587 (1992) 241-249
12. Kaakkola S., and Wurtman R.J. Effects of catecholamine-O-methyltransferase inhibitors and l-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J. Neurochem. 60 (1993) 137-144
13. Kalita J., Misra U.K., Pandey S., and Dhole T.N. A comparison of clinical and radiological findings in adults and children with Japanese encephalitis. Arch. Neurol. 60 (2003) 1760-1764
14. Keräen T., Gordin A., Harjora V.P., Karlsson M., Korpela K., Pentikainen P.J., Seppala L., and Wikberg T. The effect of catecholamine-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neurophrmacol. 16 (1993) 145-156
15. Kumar S., Kalita J., Saxena V., Khan M.Y., Khanna V.K., Sharma S., Dhole T.N., and Miara U.K. Some observations on the tropism of Japanese encephalitis virus in rat brain. Brain Res. 1268 (2009) 135-141
16. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., and Weinshilboum R. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996) 243-250
17. Lee M.S., Kim H.S., Cho E.K., Lim J.H., and Rinne J.O. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 58 (2002) 564-567
18. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
19. McLeod H.L., Syvanen A.C., Githang'a J., Indalo A., Ismail D., Dewar K., Ulmanen I., and Sludden J. Ethnic differences in catechol-O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics 8 (1998) 195-199
20. Ogata A., Hamaue N., Terado M., Minami M., Nagashima K., and Tashiro K. Isatin, an endogenous MAO inhibitor, improves bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by Japanese encephalitis virus. J. Neuro. Sci. 206 (2003) 79-83
21. Ogata A., Nagashima K., Hall W.W., Ichikawa M., Kimura-Kuroda J., and Yasui K. Japanese encephalitis virus neurotropism is dependent on the degree of neuroral maturity. J.Virol. 65 (1991) 880-886
22. Ogata A., Tashiro K., Nukuzawa S., Nagashima K., and Hall W.W. A rat model of Parkinson's disease induced by Japanese encephalitis virus. J. Neurovirol. 3 (1997) 141-147
23. Ogawa N., Hirose Y., Ohara S., Ono T., and Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 50 (1985) 435-441
24. Shintani F., Kanba S., Nakaki T., Kinoshita N., Suzuki E., Yagi G., Kato R., and Asai M. Interluekin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J. Neurosci. 13 (1993) 3574-3581
25. Wallenstein S., Zucker C.L., and Fleiss J.L. Some statistical methods useful in circulation research. Circ. Res. 47 (1980) 1-9
26. Wichmann T., and DeLong M.R. Functional and pathophysiological models of the basal ganglia. Cur. Opin. Neurobiol. 6 (1996) 751-758
27. Zhu B.T. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr. Drug Metab. 3 (2002) 321-349